In a 2014 modeling study published in Cancer, Gulati and colleagues predicted that if PSA screening continued at its current rate, 710,000 to 1.1 million men would be overdiagnosed between 2013 and 2025, but that 36,000 to 57,000 prostate cancer deaths would be prevented during that period.
A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth, according to research from Weill Cornell Medicine scientists. Their findings could pave the way for new targeted treatment approaches.
Dr. Hu speaks about techniques & practical outcomes of various partial ablation procedures performed for men with prostate cancer, most notably the High Intensity Focused Ultrasound (HIFU) procedure, which is performed at Weill Cornell Medicine.
Dr. Christopher Barbieri speaks at an US TOO prostate cancer educational seminar at Weill Cornell Medicine to discuss the role of genomics in the identification and treatment of specific subtypes of prostate cancer, precision medicine tactics, as well as emerging therapies.
The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest a correlation between the increase and a change in prostate cancer screening guidelines recommending against routine prostate-specific antigen (PSA) testing.
Incidence of metastatic prostate cancer has increased among older men as PSA screening declines (With Dr. Jim C. Hu)
The incidence of metastatic prostate cancer appears to be rising in men aged 75 years or older, according to results of a SEER analysis published in JAMA Oncology.
This increase may be linked to the U.S. Preventive Services Task Force (USPSTF) 2008 recommendation against routine PSA screenings in men aged 75 years or older and the 2012 recommendation against routine PSA screening regardless of age.